Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects
pmid: 12873798
Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects
Hypocretins, excitatory neuropeptides at monoaminergic synapses, appear to regulate human sleep-wake cycles. Undetectable cerebrospinal fluid hypocretin-1 levels are seen in narcolepsy, which is frequently associated with secondary depression. Shortened rapid eye movement latency is observed in both narcolepsy and depression. Cerebrospinal fluid hypocretin-1 levels have not been reported in mood disorders.We examined hypocretin-1 levels in 14 control and 15 depressed subjects. Cerebrospinal fluid was drawn continuously in supine subjects for 24 hours with an indwelling intrathecal catheter under entrained light-dark conditions. Depressed subjects were studied before and after 5 weeks of sertraline (n=10, three nonresponders) or bupropion (n=5, two nonresponders).Hypocretin-1 levels varied slightly (amplitude 10%) but significantly across the diurnal cycle in control subjects, with amplitude significantly reduced in depression (3%). Levels were lowest at midday, surprising for a hypothetically wake-promoting peptide. Mean hypocretin levels trended higher in depressive than in control subjects. Hypocretin-1 levels decreased modestly but significantly after sertraline (-14%) but not bupropion.Our results are consistent with previous physiologic findings in depression indicating dampened diurnal variations in hypocretin-1. The finding that sertraline but not bupropion slightly decreased cerebrospinal fluid hypocretin-1 indicates a serotoninergic influence on hypocretin tone.
- Vanderbilt University United States
- Stanford University United States
- Eli Lilly (United States) United States
- Indiana University School of Medicine United States
- Indiana University United States
Adult, Male, Depressive Disorder, Orexins, Neuropeptides, Intracellular Signaling Peptides and Proteins, Radioimmunoassay, Antidepressive Agents, Circadian Rhythm, Dopamine Uptake Inhibitors, Case-Control Studies, Sertraline, Antidepressive Agents, Second-Generation, Humans, Female, Carrier Proteins, Bupropion, Selective Serotonin Reuptake Inhibitors
Adult, Male, Depressive Disorder, Orexins, Neuropeptides, Intracellular Signaling Peptides and Proteins, Radioimmunoassay, Antidepressive Agents, Circadian Rhythm, Dopamine Uptake Inhibitors, Case-Control Studies, Sertraline, Antidepressive Agents, Second-Generation, Humans, Female, Carrier Proteins, Bupropion, Selective Serotonin Reuptake Inhibitors
1 Research products, page 1 of 1
- 2017IsRelatedTo
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).242 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 1% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
